New York, May 21, 2026, 08:05 EDT
- Aimei Health got a Nasdaq deficiency notice for not filing its March-quarter Form 10-Q, due by May 15. The 10-Q is a quarterly financial report companies send to the SEC.
- AFJK traded near $42.18 ahead of the regular U.S. open, with Nasdaq still in pre-market at press time.
- The company got a notice on May 19. It now has 60 days to either file the report or send Nasdaq a compliance plan. If Nasdaq signs off, the firm could get up to 180 days from the original deadline to comply.
Aimei Health Technology Co., Ltd is facing a new Nasdaq compliance issue as of Thursday’s U.S. session after the blank-check firm confirmed its March-quarter report was not filed on time.
AFJK isn’t a regular healthcare stock right now. It’s a blank-check company set up to buy or merge with another firm. That means listing status, timing on any deal, and how much cash is in its trust are bigger factors than typical revenue trends.
Aimei said it got a notice from Nasdaq on May 19 saying the company isn’t in compliance with Listing Rule 5250(c)(1), which covers timely filing of regular financial reports. The problem is a late Form 10-Q for the quarter ending March 31, which was due on May 15. Aimei said the notice doesn’t affect trading for now. But if it doesn’t fix the issue, it could face delisting.
Early trading for AFJK was choppy and lacked a clear read. According to Investing.com, shares last changed hands at $42.18 with the most recent pre-market trade at $42.00 on only 10 shares—a light showing that can make moves appear bigger than they are. The 52-week range is wide, from $6.75 to $130.37, showing just how much the stock has moved.
U.S. trading hadn’t started. Nasdaq’s pre-market goes from 4:00 a.m. to 9:30 a.m. ET, then regular hours run 9:30 a.m. to 4:00 p.m. ET. According to the exchange’s 2026 holiday calendar, the next scheduled closure is Memorial Day, May 25. Thursday is not listed as a holiday.
Aimei’s late quarterly report is the latest in a compliance stretch that started in April. In April, the company got a Nasdaq notice for being behind on its 2025 annual report. That 10-K was due March 31, but Aimei filed its late notice on April 1.
Aimei is still tied up with a planned business combination with United Hydrogen Group Inc. In its annual report, Aimei noted shareholders approved the United Hydrogen deal in November 2025, and the registration statement was declared effective, though the deal was still waiting on certain conditions like Chinese regulatory review.
Aimei put $34,330.96 into its trust account, it said May 6, buying another month to get a deal done. The deadline now runs to June 6. The sponsor and United Hydrogen split the funding, using a non-interest-bearing promissory note.
The company detailed in its 2025 annual report why missing the filing deadline is an issue for investors. Aimei said it was not operating as of Dec. 31 and won’t have any operating revenue until it closes a business combination. The auditor also flagged big doubts about Aimei’s ability to stay in business if it can’t finish a deal in time.
SPAC stocks traded mixed. Google Finance showed Rising Dragon Acquisition, GigCapital7 and Hall Chadwick Acquisition among related names, with no clear direction across the group. For AFJK, the market focus stayed on the filing cure window and the United Hydrogen deadline, not any broader move in SPACs.
But the risk goes both ways. A fast 10-Q, or if Nasdaq signs off on a plan, could clear the immediate listing risk. If there’s another delay, a no from Nasdaq, or if United Hydrogen slips again, holders could end up in a delisting process, fighting for another extension, or looking at liquidation instead of growth from the operating company.
